News | May 18, 2025
Indraprastha Medical Corporation posts Q4 FY25 PAT at Rs. 41.01 Cr
Indraprastha Medical Corporation has reported total income of Rs. 340.10 crores during the period ended March 31, 2025
Indraprastha Medical Corporation has reported total income of Rs. 340.10 crores during the period ended March 31, 2025
Shilpa Pharma Lifesciences, Unit-1, received EIR from USFDA
The company has posted net profit of Rs. 260.10 crores for the Financial Year ended March 31, 2025
Standalone profit from operations for the quarter were Rs. 162 crores
CuraTeQ Biologics receives approval for biosimilar Zefylti from UK’s MHRA
The company has posted net profit of Rs. 118.01 crores for the Financial Year ended March 31, 2025
ISPP will analyze health systems across states, identifying scalable models and actionable insights to strengthen India's healthcare delivery
Integrated facility to deliver end-to-end, customized workflows across life sciences, diagnostics, and applied markets
The company's first-ever corporate-level submission to EcoVadis builds on years of operational and environmental excellence
The portfolio consists of liquids and immediate release solid orals which are in the therapeutic segment to treat infections associated with UTIs
Subscribe To Our Newsletter & Stay Updated
